Phase I Trial Evaluating Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay020 in Patients With Advanced Solid Cancer
Latest Information Update: 05 Mar 2024
At a glance
- Drugs Hemay 020 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Tianjin Hemay Biotech
Most Recent Events
- 29 Feb 2024 Status changed from recruiting to discontinued.
- 25 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 25 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.